1. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1. Issue 4 (5th October 2018) Authors: Reinisch, Walter; Bressler, Brian; Curtis, Rebecca; Parikh, Asit; Yang, Huyuan; Rosario, Maria; Røseth, Arne; Danese, Silvio; Feagan, Brian; Sands, Bruce E; Ginsburg, Philip; Dassopoulos, Themistocles; Lewis, James; Xu, Jing; Wyant, Tim Journal: Inflammatory bowel diseases Issue: Volume 25:Issue 4(2019) Page Start: 803 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Corrigendum: Exposure—efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. (29th January 2018) Authors: Rosario, Maria; French, Jonathan L; Dirks, Nathanael L; Sankoh, Serap; Parikh, Asit; Yang, Huyuan; Danese, Silvio; Colombel, Jean-Frédéric; Smyth, Michael; Sandborn, William J; Feagan, Brian G; Reinisch, Walter; Sands, Bruce E; Sans, Miguel; Fox, Irving Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 4(2018:Apr.) Page Start: 510 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Issue 1 (24th April 2014) Authors: Wyant, Tim; Leach, Tim; Sankoh, Serap; Wang, Yuemei; Paolino, Jonathan; Pasetti, Marcela F; Feagan, Brian G; Parikh, Asit Journal: Gut Issue: Volume 64:Issue 1(2015) Page Start: 77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database. (2nd September 2015) Authors: McAuliffe, Megan E.; Lanes, Stephan; Leach, Timothy; Parikh, Asit; Faich, Gerald; Porter, Jane; Holick, Crystal; Esposito, Daina; Zhao, Yueqin; Fox, Irving Journal: Current medical research and opinion Issue: Volume 31:Number 9(2015:Sep.) Page Start: 1655 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Random Mutagenesis by Whole-Plasmid PCR Amplification. (March 1998) Authors: Parikh, Asit; Peter Guengerich, F. Journal: Biotechniques Issue: Volume 24:Number 3(1998) Page Start: 428 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. DOCK4 Regulation of Rho GTPases Mediates Pulmonary Vascular Barrier Function. Issue 7 (28th April 2022) Authors: Yazbeck, Pascal; Cullere, Xavier; Bennett, Paul; Yajnik, Vijay; Wang, Huan; Kawada, Kenji; Davis, Vanessa M.; Parikh, Asit; Kuo, Andrew; Mysore, Vijayashree; Hla, Timothy; Milstone, David S.; Mayadas, Tanya N. Journal: Arteriosclerosis, thrombosis, and vascular biology Issue: Volume 42:Issue 7(2022) Page Start: 886 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Issue 5 (18th February 2016) Authors: Colombel, Jean-Frédéric; Sands, Bruce E; Rutgeerts, Paul; Sandborn, William; Danese, Silvio; D'Haens, Geert; Panaccione, Remo; Loftus, Edward V; Sankoh, Serap; Fox, Irving; Parikh, Asit; Milch, Catherine; Abhyankar, Brihad; Feagan, Brian G Journal: Gut Issue: Volume 66:Issue 5(2017) Page Start: 839 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Defining Remission Using Patient‐reported Outcome Components of the Crohn's Disease Activity Index: Post‐hoc Analyses of Vedolizumab Data from the GEMINI 2 Study: 1865. (October 2015) Authors: Sandborn, William J.; Vermeire, Séverine; Sands, Bruce E.; Feagan, Brian; Shetzline, Michael; Xu, Jing; Mody, Reema; Parikh, Asit; Abhyankar, Brihad Journal: American journal of gastroenterology Issue: Volume 110(2015)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1. Issue 4 (14th March 2019) Authors: Reinisch, Walter; Bressler, Brian; Curtis, Rebecca; Parikh, Asit; Yang, Huyuan; Rosario, Maria; Røseth, Arne; Danese, Silvio; Feagan, Brian; Sands, Bruce E; Ginsburg, Philip; Dassopoulos, Themistocles; Lewis, James; Xu, Jing; Wyant, Tim Journal: Inflammatory bowel diseases Issue: Volume 25:Issue 4(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. (17th February 2017) Authors: Rosario, Maria; French, Jonathan L; Dirks, Nathanael L; Sankoh, Serap; Parikh, Asit; Yang, Huyuan; Danese, Silvio; Colombel, Jean-Frédéric; Smyth, Michael; Sandborn, William J; Feagan, Brian G; Reinisch, Walter; Sands, Bruce E; Sans, Miguel; Fox, Irving Journal: Journal of Crohn's and colitis Issue: Volume 11:Number 8(2017:Aug.) Page Start: 921 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗